search
Back to results

Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids (VAPOHYSTERO)

Primary Purpose

Uterine Fibroids

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
OHR VS OHV
Sponsored by
Assistance Publique Hopitaux De Marseille
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Uterine Fibroids

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient at least 18 years old.
  • Non-pregnant patient
  • A patient who had an ultrasound confirming the presence of a uterine fibroid to be treated less than 6 cm.
  • Patient who had a diagnostic hysteroscopy confirming the presence of a uterine fibroid to be treated of type 0, 1 or 2 according to the FIGO classification.
  • Patient presenting an indication for intra uterine fibroid resection (bleeding, fertility problems) by operative hysteroscopy.
  • Patient having agreed to participate in the study and having signed an informed consent.

Exclusion Criteria:

  • Minor patient
  • Patient not affiliated to a social security system
  • Persons benefiting from special protection: by virtue of articles L1121-5 to L1121-8 of the Public Health Code: pregnant or breast-feeding women, minors, adults under guardianship or curatorship, persons deprived of liberty.
  • Patient refusing to sign the consent or unable to receive the information necessary to give informed consent.

Sites / Locations

  • Assistance Publique Hôpitaux MarseilleRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

OHR System

OHV System

Arm Description

Use of the OHR system to perform an operative hysteroscopy by resection of the fibroid.

Use of the OHV system to perform an operative hysteroscopy by vaporization of the fibroid.

Outcomes

Primary Outcome Measures

Operative time
Operative time expressed in minutes

Secondary Outcome Measures

The amount of distention fluid used during operative hysteroscopy
Measured by collection of the distention fluid pockets at the end of the procedure
Resection time
Time estimated in cm3/min based on ultrasound measurement of the volume of the myoma involved in the resection preoperatively and postoperatively, related to the operative time
Complication rate during operative hysteroscopy
Cervical tear rate and Rate of uterine perforations
The rate of discontinuation of the operative hysteroscopy before complete resection
Rate of discontinuation because of uterine perforations, operative time greater than 60 minutes, quantity of distension fluid greater than 9 liters, deficit of distension fluid greater than 1 liter, per operative haemorrhage
The rate of postoperative synechiae in patients of childbearing age.
Rate of postoperative synechiae diagnosed at follow-up hysteroscopy in patients of childbearing age.
Operative pain
Operative pain evaluated by a visual analog scale (0-100mm). If the patient has a score of 0, it means that he/she has no pain. The higher the value, the more intense the pain.

Full Information

First Posted
September 15, 2021
Last Updated
July 25, 2023
Sponsor
Assistance Publique Hopitaux De Marseille
search

1. Study Identification

Unique Protocol Identification Number
NCT05078307
Brief Title
Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids
Acronym
VAPOHYSTERO
Official Title
Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 25, 2021 (Actual)
Primary Completion Date
November 17, 2023 (Anticipated)
Study Completion Date
May 17, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique Hopitaux De Marseille

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Operative hysteroscopy (OH) is an endoscopic technique for the treatment of benign intrauterine lesions and in particular uterine fibroids. The limit of this technique is the duration of the operation which is correlated with the operative risks. Thus, when there is a large fibroid or several fibroids, this technique can sometimes not be used or require several sessions. Today there is a new technique of HO that theoretically allows a gain in operative time. There are few comparative studies showing a clinically interesting gain in operating time. The aim of this study is to compare the operative time between the classical HO technique by resection and the vaporization technique. This is a randomized, single-center study. The study population corresponded to women aged over 18 years requiring operative hysteroscopy for fibroids. After obtaining informed consent, patients will be randomized into two groups: a vaporization hysteroscopy group and a resection hysteroscopy group. The primary endpoint will be operative time. The secondary endpoints will be intraoperative characteristics and complications (amount of distension fluid used, cervical injury, uterine perforation), immediate postoperative data (pain) and medium-term data (postoperative synechiae). The starting hypothesis is that the technique of hysteroscopy by vaporization would reduce the operative time by 30%. The number of subjects required per group will be 27 patients, or 54 patients in total over 24 months. The expected results are a significant decrease in operative time with the vaporization hysteroscopy technique. This would be important because the reduction in operative time is associated with a reduction in complications of operative hysteroscopy and the possibility of treating larger fibroids with this technique.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uterine Fibroids

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
54 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
OHR System
Arm Type
Active Comparator
Arm Description
Use of the OHR system to perform an operative hysteroscopy by resection of the fibroid.
Arm Title
OHV System
Arm Type
Experimental
Arm Description
Use of the OHV system to perform an operative hysteroscopy by vaporization of the fibroid.
Intervention Type
Procedure
Intervention Name(s)
OHR VS OHV
Intervention Description
Control group : use of the OHR system to perform an Operative Hysteroscopy by Resection of the fibroid. Experimental group : use of the OHV system to perform an Operative Hysteroscopy by Vaporization of the fibroid.
Primary Outcome Measure Information:
Title
Operative time
Description
Operative time expressed in minutes
Time Frame
Baseline
Secondary Outcome Measure Information:
Title
The amount of distention fluid used during operative hysteroscopy
Description
Measured by collection of the distention fluid pockets at the end of the procedure
Time Frame
Baseline
Title
Resection time
Description
Time estimated in cm3/min based on ultrasound measurement of the volume of the myoma involved in the resection preoperatively and postoperatively, related to the operative time
Time Frame
Baseline
Title
Complication rate during operative hysteroscopy
Description
Cervical tear rate and Rate of uterine perforations
Time Frame
Baseline
Title
The rate of discontinuation of the operative hysteroscopy before complete resection
Description
Rate of discontinuation because of uterine perforations, operative time greater than 60 minutes, quantity of distension fluid greater than 9 liters, deficit of distension fluid greater than 1 liter, per operative haemorrhage
Time Frame
Baseline
Title
The rate of postoperative synechiae in patients of childbearing age.
Description
Rate of postoperative synechiae diagnosed at follow-up hysteroscopy in patients of childbearing age.
Time Frame
between 6 and 8 weeks after the operation
Title
Operative pain
Description
Operative pain evaluated by a visual analog scale (0-100mm). If the patient has a score of 0, it means that he/she has no pain. The higher the value, the more intense the pain.
Time Frame
Baseline

10. Eligibility

Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient at least 18 years old. Non-pregnant patient A patient who had an ultrasound confirming the presence of a uterine fibroid to be treated less than 6 cm. Patient who had a diagnostic hysteroscopy confirming the presence of a uterine fibroid to be treated of type 0, 1 or 2 according to the FIGO classification. Patient presenting an indication for intra uterine fibroid resection (bleeding, fertility problems) by operative hysteroscopy. Patient having agreed to participate in the study and having signed an informed consent. Exclusion Criteria: Minor patient Patient not affiliated to a social security system Persons benefiting from special protection: by virtue of articles L1121-5 to L1121-8 of the Public Health Code: pregnant or breast-feeding women, minors, adults under guardianship or curatorship, persons deprived of liberty. Patient refusing to sign the consent or unable to receive the information necessary to give informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Aubert Agostini, MD/PhD
Phone
04 91 38 37 87
Ext
+33
Email
aubert.agostini@ap-hm.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
François CREMIEUX, Director
Organizational Affiliation
AP-HM
Official's Role
Study Director
Facility Information:
Facility Name
Assistance Publique Hôpitaux Marseille
City
Marseille
State/Province
Bouches-du-Rhone
ZIP/Postal Code
13354
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marjorie Saccone
Email
marjorie.saccone@ap-hm.fr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids

We'll reach out to this number within 24 hrs